Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07087054 · ClinicalTrials.gov registry record · Phase 3
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome, sponsored by Crinetics Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
- 20
- Study locations
NCT07087054 is a Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome that is actively recruiting participants, run by Crinetics Pharmaceuticals. The registered enrollment target is 141 participants, above the 81-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (74% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT07087054, a Phase 3 study of Carcinoid Tumor and Carcinoid Syndrome, is actively recruiting participants, sponsored by Crinetics Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paltusotine
Study Locations (20)
Other
- Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo - Buenos Aires
- Sanatorio Guemes - Buenos Aires
- Centro de Endocrinologia y Diabetes Dr. A. Gutman ICM - Investigaciones - Buenos Aires
- Instituto Médico Especializado Alexander Fleming - Buenos Aires
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Connecticut
- Yale University - New Haven Hospital - Yale Cancer Center - New Haven
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winshop Cancer Institute - Emory University - Atlanta
Iowa
- University of Iowa Health Care - Iowa City
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2025-11-19 |
| Est. Completion | 2030-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07087054
The ClinicalTrials.gov registry entry for NCT07087054 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 81-participant average among 8 other Carcinoid Tumor trials with a reported enrollment target (74% higher). The listed sponsor is Crinetics Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Carcinoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07087054 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT07087054 about?
NCT07087054 is a clinical study titled "Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen". A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to c...
What is the current status of trial NCT07087054?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2025-11-19. Estimated completion is 2030-01.
What conditions does trial NCT07087054 study?
This clinical trial studies the following conditions: Carcinoid Tumor, Carcinoid Syndrome, Carcinoid, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum.
What interventions are being tested in trial NCT07087054?
The interventions under investigation include: Placebo (DRUG), Paltusotine (DRUG).
Who is sponsoring clinical trial NCT07087054?
This trial is sponsored by Crinetics Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07087054 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.